Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RxSight, Inc.RXST · Entity 1226 | Chief Operating Officer | September 05, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RxSight, Inc.
Report date September 05, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2031-07-30 | Direct | 0 |
Reported balance
After 2026-09-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-05 · Disposition to issuer · Disposed 98,367 · Balance 0 F1: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.33:1 basis with a post-exchange exercise price of $6.375 per share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.95 · Expires 2033-03-08 | Direct | 0 |
Reported balance
After 2026-09-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-05 · Disposition to issuer · Disposed 120,000 · Balance 0 F3: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.15:1 basis with a post-exchange exercise price of $6.375 per share. F2: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 9, 2023. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.07 · Expires 2034-03-03 | Direct | 0 |
Reported balance
After 2026-09-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-05 · Disposition to issuer · Disposed 92,200 · Balance 0 F5: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.55:1 basis with a post-exchange exercise price of $6.375 per share. F4: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 4, 2024. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.24 · Expires 2034-08-06 | Direct | 0 |
Reported balance
After 2026-09-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-05 · Disposition to issuer · Disposed 50,000 · Balance 0 F5: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.55:1 basis with a post-exchange exercise price of $6.375 per share. F6: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean August 7, 2024. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.21 · Expires 2035-02-26 | Direct | 0 |
Reported balance
After 2026-09-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-05 · Disposition to issuer · Disposed 125,000 · Balance 0 F1: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.33:1 basis with a post-exchange exercise price of $6.375 per share. F7: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 27, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.38 · Expires 2033-09-04 | Direct | 73,960 |
Reported balance
After 2026-09-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-05 · Grant · Acquired 73,960 · Balance 73,960 F1: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.33:1 basis with a post-exchange exercise price of $6.375 per share. F8: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the shares subject to the option will vest on February 28, 2027 and the remaining 75% of the shares subject to the option will vest on August 31, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.38 · Expires 2033-09-04 | Direct | 104,347 |
Reported balance
After 2026-09-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-05 · Grant · Acquired 104,347 · Balance 104,347 F3: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.15:1 basis with a post-exchange exercise price of $6.375 per share. F9: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 89,129 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 89,129 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 15,218 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.38 · Expires 2033-09-04 | Direct | 59,483 |
Reported balance
After 2026-09-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-05 · Grant · Acquired 59,483 · Balance 59,483 F5: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.55:1 basis with a post-exchange exercise price of $6.375 per share. F10: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 37,177 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 37,177 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 22,306 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.38 · Expires 2033-09-04 | Direct | 32,258 |
Reported balance
After 2026-09-05 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-05 · Grant · Acquired 32,258 · Balance 32,258 F5: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.55:1 basis with a post-exchange exercise price of $6.375 per share. F11: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 16,129 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 16,129 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 16,129 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.38 · Expires 2033-09-04 | Direct | 93,984 |
Reported balance
After 2026-09-05 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-05 · Grant · Acquired 93,984 · Balance 93,984 F1: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.33:1 basis with a post-exchange exercise price of $6.375 per share. F12: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 35,244 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 35,244 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 58,740 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.33:1 basis with a post-exchange exercise price of $6.375 per share.
F2: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 9, 2023.
F3: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.15:1 basis with a post-exchange exercise price of $6.375 per share.
F4: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 4, 2024.
F5: On September 5, 2026, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1.55:1 basis with a post-exchange exercise price of $6.375 per share.
F6: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean August 7, 2024.
F7: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 27, 2025.
F8: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the shares subject to the option will vest on February 28, 2027 and the remaining 75% of the shares subject to the option will vest on August 31, 2027.
F9: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 89,129 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 89,129 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 15,218 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter.
F10: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 37,177 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 37,177 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 22,306 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter.
F11: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 16,129 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 16,129 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 16,129 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter.
F12: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the 35,244 shares subject to the option will vest on February 28, 2027 and the remaining 75% of the 35,244 shares subject to the option will vest on August 31, 2027. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one twenty-fourth (1/24th) of the 58,740 shares subject to the option will vest on February 28, 2027 and in equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 08, 2024 Filed Jan 9, 2024 21:05 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 5,000 | $42.00 | $210,000.00 |
DisclosureSEC source: 0000950170-24-003327 · ownership.xml · nonDerivative · entry 2 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,475 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. Read SEC document |
| January 08, 2024 Filed Jan 9, 2024 21:05 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 15,000 | $15.08 | $226,200.00 |
DisclosureSEC source: 0000950170-24-003327 · ownership.xml · nonDerivative · entry 1 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2023 Filed Dec 26, 2023 21:10 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $15.08 | $0.00 |
DisclosureSEC source: 0001209191-23-059680 · doc4.xml · derivative · entry 4 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,207 Underlying: Common Stock · 5,000 shares Expires 2030-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2015 Equity Incentive Plan, as amended) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 23, 2020. Read SEC document |
| December 22, 2023 Filed Dec 26, 2023 21:10 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 5,000 | $40.00 | $200,000.00 |
DisclosureSEC source: 0001209191-23-059680 · doc4.xml · nonDerivative · entry 2 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,475 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. Read SEC document |
| December 22, 2023 Filed Dec 26, 2023 21:10 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 5,000 | $15.08 | $75,400.00 |
DisclosureSEC source: 0001209191-23-059680 · doc4.xml · nonDerivative · entry 1 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 23:07 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $15.08 | $0.00 |
DisclosureSEC source: 0001209191-23-059385 · doc4.xml · derivative · entry 9 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,207 Underlying: Common Stock · 10,000 shares Expires 2030-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2015 Equity Incentive Plan, as amended) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 23, 2020. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 23:07 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 937 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001209191-23-059385 · doc4.xml · derivative · entry 8 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,843 Underlying: Common Stock · 937 shares Expires 2027-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 23:07 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 5,000 | $39.09 | $195,470.00 |
DisclosureSEC source: 0001209191-23-059385 · doc4.xml · nonDerivative · entry 6 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,475 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 5,000 shares sold in the price range of $39.00 to $39.45 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 23:07 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 106 | $39.45 | $4,181.70 |
DisclosureSEC source: 0001209191-23-059385 · doc4.xml · nonDerivative · entry 5 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,475 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 23:07 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 4,894 | $38.93 | $190,527.34 |
DisclosureSEC source: 0001209191-23-059385 · doc4.xml · nonDerivative · entry 4 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,581 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. F3 · price: Represents the weighted average share price of an aggregate total of 4,894 shares sold in the price range of $38.41 to $39.39 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 23:07 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 937 | $38.99 | $36,530.82 |
DisclosureSEC source: 0001209191-23-059385 · doc4.xml · nonDerivative · entry 3 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,475 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2023 by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 937 shares sold in the price range of $38.45 to $39.45 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 23:07 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 10,000 | $15.08 | $150,800.00 |
DisclosureSEC source: 0001209191-23-059385 · doc4.xml · nonDerivative · entry 2 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 23:07 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 937 | $4.13 | $3,869.81 |
DisclosureSEC source: 0001209191-23-059385 · doc4.xml · nonDerivative · entry 1 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 26, 2023 Filed Jul 27, 2023 20:44 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionStock Option (right to buy) · Derivative | 25,475 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0001209191-23-043543 · doc4.xml · derivative · entry 3 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,667 Underlying: Common Stock · 25,475 shares Expires 2025-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 26, 2023 Filed Jul 27, 2023 20:44 UTC | RxSight, Inc. RXST · Entity 1226 | Exercise / conversionCommon Stock | 25,475 | $3.93 | $99,999.57 |
DisclosureSEC source: 0001209191-23-043543 · doc4.xml · nonDerivative · entry 1 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 21:14 UTC | RxSight, Inc. RXST · Entity 1226 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0001209191-23-017799 · doc4.xml · derivative · entry 1 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2033-03-09 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 9, 2023. Read SEC document |
| August 05, 2021 Filed Aug 7, 2021 00:54 UTC | RxSight, Inc. RXST · Entity 1226 | PurchaseCommon Stock | 1,372 | $13.69 | $18,782.68 |
DisclosureSEC source: 0000899243-21-031997 · doc4.xml · nonDerivative · entry 2 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,372 F2 · price: Represents the weighted average share price of an aggregate total of 1,372 shares purchased in the price range of $13.61 to $13.9599 by the Reporting Person's spouse. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. F3 · balance_after: The shares reported as beneficially held include a de minimus adjustment of 0.366 shares due to the rounding up of fractional shares Read SEC document |
| August 05, 2021 Filed Aug 7, 2021 00:54 UTC | RxSight, Inc. RXST · Entity 1226 | PurchaseCommon Stock | 1,000 | $14.49 | $14,492.20 |
DisclosureSEC source: 0000899243-21-031997 · doc4.xml · nonDerivative · entry 1 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · price: Represents the weighted average share price of an aggregate total of 1,000 shares purchased in the price range of $14.46 to $14.60 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 31, 2021 Filed Aug 3, 2021 00:27 UTC | RxSight, Inc. RXST · Entity 1226 | GrantStock option (right to buy) · Derivative | 98,367 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031113 · doc4.xml · derivative · entry 1 Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,367 Underlying: Common Stock · 98,367 shares Expires 2031-07-31 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean July 30, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.